{"id":535560,"date":"2021-09-08T08:31:05","date_gmt":"2021-09-08T12:31:05","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecises-dutch-subsidiary-receives-french-research-tax-credit-cir-accreditation\/"},"modified":"2021-09-08T08:31:05","modified_gmt":"2021-09-08T12:31:05","slug":"immunoprecises-dutch-subsidiary-receives-french-research-tax-credit-cir-accreditation","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecises-dutch-subsidiary-receives-french-research-tax-credit-cir-accreditation\/","title":{"rendered":"ImmunoPrecise\u2019s Dutch Subsidiary Receives French Research Tax Credit (CIR) Accreditation"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistdisc { list-style-type: disc }\n.bwpagebreakafter { page-break-after: always }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>ImmunoPrecise\u2019s Dutch Subsidiary <\/b><b>Receives French Research Tax Credit (CIR) Accreditation<\/b><\/p>\n<p>VICTORIA, British Columbia&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nIMMUNOPRECISE ANTIBODIES LTD. (the \u201cCompany\u201d or \u201cIPA\u201d) (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, announced today that its site in Oss, the Netherlands, which is part of the Company\u2019s subsidiary, IPA Europe, has been granted a three-year approval for the \u201cCr\u00e9dit d&#8217;Imp\u00f4t Recherche\u201d (CIR) from the French Ministry of Higher Education and Research. CIR is a French R&amp;D tax credit initiative which will provide tax credits to eligible French companies when they engage IPA Europe, Oss, in qualified research and development activities.\n<\/p>\n<p><b>The CIR rate that an eligible French customer purchasing services from IPA Europe may receive varies depending on the amount invested: <\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\n30% for eligible R&amp;D expenses up to \u20ac100 million of R&amp;D activities, 5% above that amount\n<\/li>\n<li>\n20% for eligible innovation expenditure (for SMEs only) of up to \u20ac400,000\n<\/li>\n<\/ul>\n<p><b>An Added Benefit to the Full-Service Advantage of IPA<\/b><\/p>\n<p>\nDr Stefan Lang, Chief Business Officer of IPA, commented: \u201cWe are pleased to offer this accreditation to eligible French companies who engage with IPA in Oss in fundamental and applied research and experimental development activities. IPA is privileged to be able to pass this recognition of our role in research and innovation in scientific antibody discovery in Europe, onto existing and new French partners, in the form of tax relief.\u201d\n<\/p>\n<p><b>About CIR<\/b><\/p>\n<p>\nFor more information about the French CIR R&amp;D tax credit initiative, go to:<br \/>\n<br \/><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.impots.gouv.fr%2Fportail%2Finternational-professionnel%2Ftax-incentives&amp;esheet=52488006&amp;newsitemid=20210908005688&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.impots.gouv.fr%2Fportail%2Finternational-professionnel%2Ftax-incentives&amp;index=1&amp;md5=8b104e6cfefc00020f2029a1b1baeb2b\">https:\/\/www.impots.gouv.fr\/portail\/international-professionnel\/tax-incentives<\/a><\/p>\n<p><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.enseignementsup-recherche.gouv.fr%2Fcid114521%2Fguide-du-credit-d-impot-recherche-2020.html&amp;esheet=52488006&amp;newsitemid=20210908005688&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.enseignementsup-recherche.gouv.fr%2Fcid114521%2Fguide-du-credit-d-impot-recherche-2020.html&amp;index=2&amp;md5=a586036c6a8a62813dc0c227c94d196e\">https:\/\/www.enseignementsup-recherche.gouv.fr\/cid114521\/guide-du-credit-d-impot-recherche-2020.html<\/a><\/p>\n<p><b>ImmunoPrecise Antibodies Ltd.<\/b><\/p>\n<p>\nImmunoPrecise is an innovation-driven technology platform company that supports its business partners in their quest to discover and develop novel antibodies against a broad range of classes of disease targets. The Company aims to transform the conventional multi-vendor antibody discovery model by providing a comprehensive suite of services tailored to optimize antibody genetic diversity and epitope coverage, to discover antibodies against rare and\/or challenging epitopes. For further information, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.immunoprecise.com&amp;esheet=52488006&amp;newsitemid=20210908005688&amp;lan=en-US&amp;anchor=www.immunoprecise.com&amp;index=3&amp;md5=e59a4346407a336054996b2115784044\">www.immunoprecise.com<\/a>.\n<\/p>\n<div class=\"bwpagebreakafter\" \/>\n<p><b>Forward Looking Information<\/b><\/p>\n<p>\nThis news release contains forward-looking statements within the meaning of applicable United States securities laws and Canadian securities laws. Forward-looking statements are often identified by the use of words such as \u201cpotential\u201d, \u201cplans\u201d, \u201cexpects\u201d or \u201cdoes not expect\u201d, \u201cis expected\u201d, \u201cestimates\u201d, \u201cintends\u201d, \u201canticipates\u201d or \u201cdoes not anticipate\u201d, or \u201cbelieves\u201d, or variations of such words and phrases or state that certain actions, events or results \u201cmay\u201d, \u201ccould\u201d, \u201cwould\u201d, \u201cmight\u201d or \u201cwill\u201d be taken, occur or be achieved. Forward-looking information contained in this news release include, but are not limited to, statements regarding the potential availability or benefit of the French CIR tax credit to IPA Europe\u2019s customers. In respect of the forward-looking information contained herein, the Company has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time.\n<\/p>\n<p>\nForward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Actual results could differ materially from those currently anticipated due to a number of factors and risks, including, whether changes to the French CIR tax credit program, as well as those risks discussed in the Company\u2019s Annual Information Form dated July 27, 2021 (which may be viewed on the Company\u2019s profile at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sedar.com%2F&amp;esheet=52488006&amp;newsitemid=20210908005688&amp;lan=en-US&amp;anchor=www.sedar.com&amp;index=4&amp;md5=97fb41279e84d657ca902bf4bd7f64ce\">www.sedar.com<\/a>) and the Company\u2019s Form 40-F dated July 27, 2021 (which may be viewed on the Company\u2019s profile at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=52488006&amp;newsitemid=20210908005688&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=5&amp;md5=047cc456ba866d71d29b14ee5c5616fb\">www.sec.gov<\/a>). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. Accordingly, readers should not place undue reliance on forward-looking information contained in this news release.\n<\/p>\n<p>\nThe forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. The Company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law.\n<\/p>\n<p>\nNeither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210908005688r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20210908005688\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20210908005688\/en\/<\/a><\/span><\/p>\n<p><b>Investor contact:<br \/>\n<\/b><br \/>LifeSci Advisors<br \/>\n<br \/>John Mullaly<br \/>\n<br \/>Email: <a rel=\"nofollow\" href=\"mailto:jmullaly@lifesciadvisors.com\">jmullaly@lifesciadvisors.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Europe North America Canada France<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Infectious Diseases Biotechnology Pharmaceutical Health<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20210908005688\/en\/1035853\/3\/ImmunoPrecise_logo_HZ_PMS.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>ImmunoPrecise\u2019s Dutch Subsidiary Receives French Research Tax Credit (CIR) Accreditation VICTORIA, British Columbia&#8211;(BUSINESS WIRE)&#8211; IMMUNOPRECISE ANTIBODIES LTD. (the \u201cCompany\u201d or \u201cIPA\u201d) (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, announced today that its site in Oss, the Netherlands, which is part of the Company\u2019s subsidiary, IPA Europe, has been granted a three-year approval for the \u201cCr\u00e9dit d&#8217;Imp\u00f4t Recherche\u201d (CIR) from the French Ministry of Higher Education and Research. CIR is a French R&amp;D tax credit initiative which will provide tax credits to eligible French companies when they engage IPA Europe, Oss, in qualified research and development activities. The CIR rate that an eligible French customer purchasing services from IPA Europe may receive varies depending &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecises-dutch-subsidiary-receives-french-research-tax-credit-cir-accreditation\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;ImmunoPrecise\u2019s Dutch Subsidiary Receives French Research Tax Credit (CIR) Accreditation&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-535560","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ImmunoPrecise\u2019s Dutch Subsidiary Receives French Research Tax Credit (CIR) Accreditation - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecises-dutch-subsidiary-receives-french-research-tax-credit-cir-accreditation\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ImmunoPrecise\u2019s Dutch Subsidiary Receives French Research Tax Credit (CIR) Accreditation - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ImmunoPrecise\u2019s Dutch Subsidiary Receives French Research Tax Credit (CIR) Accreditation VICTORIA, British Columbia&#8211;(BUSINESS WIRE)&#8211; IMMUNOPRECISE ANTIBODIES LTD. (the \u201cCompany\u201d or \u201cIPA\u201d) (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, announced today that its site in Oss, the Netherlands, which is part of the Company\u2019s subsidiary, IPA Europe, has been granted a three-year approval for the \u201cCr\u00e9dit d&#8217;Imp\u00f4t Recherche\u201d (CIR) from the French Ministry of Higher Education and Research. CIR is a French R&amp;D tax credit initiative which will provide tax credits to eligible French companies when they engage IPA Europe, Oss, in qualified research and development activities. The CIR rate that an eligible French customer purchasing services from IPA Europe may receive varies depending &hellip; Continue reading &quot;ImmunoPrecise\u2019s Dutch Subsidiary Receives French Research Tax Credit (CIR) Accreditation&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecises-dutch-subsidiary-receives-french-research-tax-credit-cir-accreditation\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-08T12:31:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210908005688r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunoprecises-dutch-subsidiary-receives-french-research-tax-credit-cir-accreditation\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunoprecises-dutch-subsidiary-receives-french-research-tax-credit-cir-accreditation\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"ImmunoPrecise\u2019s Dutch Subsidiary Receives French Research Tax Credit (CIR) Accreditation\",\"datePublished\":\"2021-09-08T12:31:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunoprecises-dutch-subsidiary-receives-french-research-tax-credit-cir-accreditation\\\/\"},\"wordCount\":804,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunoprecises-dutch-subsidiary-receives-french-research-tax-credit-cir-accreditation\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210908005688r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunoprecises-dutch-subsidiary-receives-french-research-tax-credit-cir-accreditation\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunoprecises-dutch-subsidiary-receives-french-research-tax-credit-cir-accreditation\\\/\",\"name\":\"ImmunoPrecise\u2019s Dutch Subsidiary Receives French Research Tax Credit (CIR) Accreditation - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunoprecises-dutch-subsidiary-receives-french-research-tax-credit-cir-accreditation\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunoprecises-dutch-subsidiary-receives-french-research-tax-credit-cir-accreditation\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210908005688r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2021-09-08T12:31:05+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunoprecises-dutch-subsidiary-receives-french-research-tax-credit-cir-accreditation\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunoprecises-dutch-subsidiary-receives-french-research-tax-credit-cir-accreditation\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunoprecises-dutch-subsidiary-receives-french-research-tax-credit-cir-accreditation\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210908005688r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210908005688r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunoprecises-dutch-subsidiary-receives-french-research-tax-credit-cir-accreditation\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ImmunoPrecise\u2019s Dutch Subsidiary Receives French Research Tax Credit (CIR) Accreditation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ImmunoPrecise\u2019s Dutch Subsidiary Receives French Research Tax Credit (CIR) Accreditation - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecises-dutch-subsidiary-receives-french-research-tax-credit-cir-accreditation\/","og_locale":"en_US","og_type":"article","og_title":"ImmunoPrecise\u2019s Dutch Subsidiary Receives French Research Tax Credit (CIR) Accreditation - Market Newsdesk","og_description":"ImmunoPrecise\u2019s Dutch Subsidiary Receives French Research Tax Credit (CIR) Accreditation VICTORIA, British Columbia&#8211;(BUSINESS WIRE)&#8211; IMMUNOPRECISE ANTIBODIES LTD. (the \u201cCompany\u201d or \u201cIPA\u201d) (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, announced today that its site in Oss, the Netherlands, which is part of the Company\u2019s subsidiary, IPA Europe, has been granted a three-year approval for the \u201cCr\u00e9dit d&#8217;Imp\u00f4t Recherche\u201d (CIR) from the French Ministry of Higher Education and Research. CIR is a French R&amp;D tax credit initiative which will provide tax credits to eligible French companies when they engage IPA Europe, Oss, in qualified research and development activities. The CIR rate that an eligible French customer purchasing services from IPA Europe may receive varies depending &hellip; Continue reading \"ImmunoPrecise\u2019s Dutch Subsidiary Receives French Research Tax Credit (CIR) Accreditation\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecises-dutch-subsidiary-receives-french-research-tax-credit-cir-accreditation\/","og_site_name":"Market Newsdesk","article_published_time":"2021-09-08T12:31:05+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210908005688r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecises-dutch-subsidiary-receives-french-research-tax-credit-cir-accreditation\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecises-dutch-subsidiary-receives-french-research-tax-credit-cir-accreditation\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"ImmunoPrecise\u2019s Dutch Subsidiary Receives French Research Tax Credit (CIR) Accreditation","datePublished":"2021-09-08T12:31:05+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecises-dutch-subsidiary-receives-french-research-tax-credit-cir-accreditation\/"},"wordCount":804,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecises-dutch-subsidiary-receives-french-research-tax-credit-cir-accreditation\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210908005688r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecises-dutch-subsidiary-receives-french-research-tax-credit-cir-accreditation\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecises-dutch-subsidiary-receives-french-research-tax-credit-cir-accreditation\/","name":"ImmunoPrecise\u2019s Dutch Subsidiary Receives French Research Tax Credit (CIR) Accreditation - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecises-dutch-subsidiary-receives-french-research-tax-credit-cir-accreditation\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecises-dutch-subsidiary-receives-french-research-tax-credit-cir-accreditation\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210908005688r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2021-09-08T12:31:05+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecises-dutch-subsidiary-receives-french-research-tax-credit-cir-accreditation\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecises-dutch-subsidiary-receives-french-research-tax-credit-cir-accreditation\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecises-dutch-subsidiary-receives-french-research-tax-credit-cir-accreditation\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210908005688r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210908005688r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecises-dutch-subsidiary-receives-french-research-tax-credit-cir-accreditation\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"ImmunoPrecise\u2019s Dutch Subsidiary Receives French Research Tax Credit (CIR) Accreditation"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/535560","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=535560"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/535560\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=535560"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=535560"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=535560"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}